Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease (Q39360251)

11 September 2017

Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease (English)

1 reference

gastroesophageal reflux disease

11 September 2017

0 references

(RS)-rabeprazole

0 references

author name string

Peter J Kahrilas

1

1 reference

11 September 2017

Philip Miner

2

1 reference

11 September 2017

John Johanson

3

1 reference

11 September 2017

Lian Mao

4

1 reference

11 September 2017

Leonard Jokubaitis

5

1 reference

11 September 2017

Sheldon Sloan

6

1 reference

11 September 2017

1 November 2005

1 reference

Digestive Diseases and Sciences

11 September 2017

1 reference

11 September 2017

50

1 reference

11 September 2017

11

1 reference

11 September 2017

2009-2018

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-005-3000-3

11 September 2017

0 references

cites work

Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Determination of criteria and relation to endoscopy

1 reference

12 December 2020

The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording

1 reference

12 December 2020

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

1 reference

12 December 2020

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

1 reference

12 December 2020

Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD.

1 reference

12 December 2020

Sustained esophageal contraction: a motor correlate of heartburn symptom

1 reference

12 December 2020

The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring

1 reference

12 December 2020

Duodenal fat intensifies the perception of heartburn

1 reference

12 December 2020

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

1 reference

12 December 2020

Critical issues in the management of gastroesophageal reflux disease.

1 reference

12 December 2020

The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data

1 reference

12 December 2020

Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis

1 reference

12 December 2020

Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux

1 reference

12 December 2020

Functional esophageal disorders

1 reference

12 December 2020

Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis

1 reference

12 December 2020

A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

1 reference

12 December 2020

Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group

1 reference

12 December 2020

Pathophysiology and pharmacological treatment of gastroesophageal reflux disease

1 reference

12 December 2020

Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole.

1 reference

12 December 2020

Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease

1 reference

12 December 2020

Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response

1 reference

12 December 2020

Can We Alter the Cytokine Balance in the Management of Infectious Diseases?

1 reference

12 December 2020

Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group

1 reference

12 December 2020

Gastroesophageal reflux: practical management of a common, challenging disorder

1 reference

12 December 2020

Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association

1 reference

12 December 2020

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

12 December 2020

Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents

1 reference

12 December 2020

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

1 reference

12 December 2020

The impact of gastroesophageal reflux disease on health-related quality of life.

1 reference

12 December 2020

10.1007/S10620-005-3000-3

Identifiers

DOI

1 reference

release_6scehmpm6vfqrkzkjlpmusngei

11 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6scehmpm6vfqrkzkjlpmusngei

24 November 2022

mapped directly with Wikidata item

1 reference